Recently, a study found that GBM promotes the migration of immature neutrophils from the skull bone marrow to the tumor microenvironment, where they differentiate into “hybrid” TANs with antigen-presenting capabilities under the influence of tumor-secreted factors such as GM-CSF and IFN-γ [144]. The gene discussed is CSF2; the disease is neoplasm.